The sheer volume of new drugs introduced into psychiatry within the past decade has created an urgency to get to the point as quickly as possible: Is Drug B better than A, and, if so, what about B and C? With some abatement of the tide of new compounds it becomes possible to look, not just for a quick answer, but at some of the conditions of the trial which determine the outcome.
No takes yet. Share an insight, caveat, or question.
Sandifer et al. (1965) studied this question.
Synapse has enriched one closely related paper. Consider it for comparative context: